- iBio, Inc. is a plant-based biotechnology company and biologics contract manufacturing and development organization now undergoing a comprehensive strategy change following the March 2021 changes.
- iBio's management has seen very aggressive changes during 2020-2021 with a new CEO (Mar. 2020), a new CFO (Feb 2021), a new COO (Dec. 2020), and a new CSO (Jan.2021).
- iBio is in a strong financial position following recent capital raises bringing in an additional +$70M with a new cash basis of $108M (Dec. 2020) outlining 2-3 years of funding.
- iBio's new therapeutic and vaccine focus has established a pipeline of 4 pre-clinical therapeutics for human use and 1 clinical vaccine for animal use.
- In summary, the author projects iBio, Inc. as a risky "hold" with some forward prospects.
For further details see:
iBio: New Strategy And Management Changes May Bring A Much-Needed Reset